NASDAQ: CNTACentessa Pharmaceuticals PLC Stock
$12.38+0.34 (+2.82%)
Updated Jun 13, 2025
CNTA Price
$12.38
Fair Value Price
$2.32
Market Cap
$1.65B
52 Week Low
$8.46
52 Week High
$19.09
P/E
-6.59x
P/B
4.28x
P/S
127.54x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.00M
Earnings
-$223.85M
Gross Margin
100%
Operating Margin
-1,397.65%
Profit Margin
-1,492.3%
Debt to Equity
0.37
Operating Cash Flow
-$162M
Beta
1
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CNTA Overview
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company developing treatments for a range of therapeutic areas including oncology, hematology, immunology/inflammation, neuroscience, hepatology, pulmonology, and nephrology. It focuses on rare diseases with significant unmet need. The company's pipeline includes Lixivaptan), SerpinPC, and Imgatuzumab. Centessa Pharmaceuticals was incorporated in 2020 and is based in Altrincham, U.K.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CNTA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CNTA
Ranked#99 of 464
Ranked#99 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important CNTA news, forecast changes, insider trades & much more!
CNTA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CNTA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CNTA ($12.38) is overvalued by 432.78% relative to our estimate of its Fair Value price of $2.32 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CNTA ($12.38) is not significantly undervalued (432.78%) relative to our estimate of its Fair Value price of $2.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CNTA due diligence checks available for Premium users.
Valuation
CNTA fair value
Fair Value of CNTA stock based on Discounted Cash Flow (DCF)
Price
$12.38
Fair Value
$2.32
Overvalued by
432.78%
CNTA ($12.38) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CNTA ($12.38) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CNTA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CNTA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.59x
Industry
-108.97x
Market
31.36x
CNTA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.28x
Industry
4.66x
CNTA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CNTA's financial health
Profit margin
Revenue
$15.0M
Net Income
-$26.1M
Profit Margin
-174.2%
CNTA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CNTA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$527.8M
Liabilities
$141.6M
Debt to equity
0.37
CNTA's short-term assets ($347.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CNTA's short-term assets ($347.72M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CNTA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$57.2M
Investing
-$222.4M
Financing
$3.1M
CNTA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CNTA vs Biotech Stocks
Centessa Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.